A Comprehensive Guide to Optimizing Your Small Molecule Drug Development Strategy 

Given that small molecules make up more than 50% of the drug development pipeline, adopting a proactive non-clinical to clinical strategy is crucial for accelerating your program.

A holistic bioanalysis strategy that incorporates spatial analysis allows researchers to produce quality data, identify drug targets, evaluate efficacy, and optimize delivery. Join industry experts Troy Voelker and Corinne Ramos as they cover a step-by-step approach to a rugged method, including:

  • Strategies moving from pre-clinical to clinical
  • Spatial bioanalysis and moving into GLP
  • Molecule stability and reproducibility
  • Handling matrices and compounds
  • Different instrumentation and uses
  • Cold storage check list
  • Ongoing use of ICH M-10

View our on-demand webinar to learn how to implement a comprehensive strategy that expedites the development of your small molecule.

View Webinar

Oligonucleotides: A Bioanalytical CRO’s Perspective on Current and Future State

Since the first oligonucleotide (OGNT) drug was approved by the FDA for clinical use in 1998, the industry has made significant progress in the advancement of techniques, technology, and development methods. However, due to the complexity and sensitivity of OGNTs, there are still challenges to navigate and overcome within drug development and bioanalytical analysis.

Join oligonucleotide bioanalysis SME Troy Voelker, Director of Laboratory Operations at Aliri, as he discusses:

  • Current and future state of the bioanalysis of OGNTs
  • Common approaches to bioanalysis of OGNTs
  • Evaluating and selecting the optimal and strategic approach

View Webinar